Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
Peters, S; Dafni, U; Boyer, M; De Ruysscher, D; Faivre-Finn, C; Felip, E; Garrido, P; Girard, N; Guckenberger, M; Haanen, J; Le Pechoux, C; Mornex, F; Ozsahin, M; Paz-Ares, L; Planchard, D; Raben, D; Ramalingam, S; Reck, M; Smit, E; Stahel, R; Stenzi
Peters, S (reprint author), Lausanne Univ, Dept Oncol, Lausanne, Switzerland.; Peters, S (reprint author), CHU Vaudois, Lausanne, Switzerland.
ANNALS OF ONCOLOGY, 2019; 30 (2): 161
